Clinical Trials on Lymphoma, Hodgkin in Netherlands

Total 278 results

Genentech, Inc.

Completed

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkins Lymphoma

United States, France, Canada, Netherlands
Radboud University Medical Center

Unknown

PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care

Non-Hodgkin Lymphoma

Netherlands
UMC Utrecht
ZonMw: The Netherlands Organisation for Health Research and Development

Completed

Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas

Non-Hodgkin's Lymphoma | Hodgkin's Disease | Malignant Lymphoma

Netherlands
Novartis Pharmaceuticals

Completed

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

Neoplasms | Non-Hodgkin Lymphoma

United States, Netherlands
European Organisation for Research and Treatment...
Stichting Hemato-Oncologie voor Volwassenen Nederland; Lymphoma Trials Office

Terminated

Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom, Netherlands
UMC Utrecht
Stichting Kinderen Kankervrij (KiKa)

Completed

Whole-body MRI in Pediatric Hodgkin's Lymphoma

Hodgkin's Lymphoma

Netherlands, Austria, Italy, Spain
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Bristol-Myers Squibb

Active, not recruiting

A Rollover Study of CC-122

Non-Hodgkin Lymphoma

Netherlands, France, United States, Japan
Commissie Voor Klinisch Toegepast Onderzoek

Unknown

Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

Netherlands
Regeneron Pharmaceuticals

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1)

B-cell Non-Hodgkins Lymphoma (B-NHL)

United States, Spain, United Kingdom, Netherlands
Novartis Pharmaceuticals

Completed

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) (PATH)

Hodgkin's Lymphoma

United States, Belgium, Germany, Canada, Singapore, Netherlands, France, Australia, Russian Federation, Israel, Brazil, Italy, New Zealand, Poland
Genzyme, a Sanofi Company

Completed

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (PREDICT)

Transplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line Mobilization

Netherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
European Organisation for Research and Treatment...

Terminated

Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma

Lymphoma

France, Belgium, Denmark, Egypt, Netherlands, Croatia
European Organisation for Research and Treatment...
Fondazione Italiana Linfomi ONLUS; Lymphoma Study Association

Unknown

Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma (H10)

Lymphoma

Netherlands
Kite, A Gilead Company

Active, not recruiting

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Spain, United States, Czechia, Sweden, Germany, Belgium, Italy, Canada, France, Netherlands, Poland
Nordic Nanovector
ICON Clinical Research

Active, not recruiting

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)

Follicular Lymphoma | Non-Hodgkin Lymphoma

United States, Korea, Republic of, Australia, Austria, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Singapore, Spain, Sweden, Switzerland, Turkey, United Kingdom
Sheba Medical Center
City of Hope Medical Center; Amsterdam UMC, location VUmc; University of Göttingen

Completed

Zevalin-beam for Aggressive Lymphoma

Non-Hodgkin's Lymphoma

United States, Netherlands, Germany, Israel
Celgene

Completed

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Lymphoma, Non-Hodgkin | Precursor Cell Lymphoblastic Leukemia-Lymphoma

Spain, Netherlands, United States, France, Germany, Italy
Commissie Voor Klinisch Toegepast Onderzoek

Completed

Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

Netherlands, Belgium
Bristol-Myers Squibb

Completed

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (CheckMate 205)

Hodgkin Disease

Canada, United States, Belgium, Austria, Czechia, Germany, Italy, Netherlands, Spain, United Kingdom
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Genentech, Inc.

Completed

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (ROMULUS)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, Canada, France, Italy, Germany, Netherlands
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
University of Aarhus

Active, not recruiting

Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

Malignant Lymphoma

Netherlands, Norway, Denmark, Finland, Sweden
Centre for Human Drug Research, Netherlands
Leiden University Medical Center; Micreos

Enrolling by invitation

Skin Barrier and Microbiome of CTCL Patients

Lymphoma, T-Cell, Cutaneous

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic...

Netherlands
St. Antonius Hospital

Completed

Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab (Rituxivac)

Non-Hodgkin Lymphoma (NHL)

Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (HOVON 136 NHL)

DLBCL

Netherlands
Millennium Pharmaceuticals, Inc.

Completed

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma | Relapsed or Refractory Anaplastic Large-cell Lymphoma

United States, France, United Kingdom, Germany, Spain, Netherlands, Italy, Mexico
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

France, Netherlands, Belgium, United Kingdom, Egypt, Switzerland, Portugal
European Organisation for Research and Treatment...

Active, not recruiting

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study (COBRA)

Advanced Hodgkin Lymphoma

Belgium, Spain, Netherlands, Denmark, Poland, Portugal, Slovakia
University Medical Center Groningen

Recruiting

PD-L1 PET-imaging During CAR T-cell Therapy

Large B-cell Lymphoma

Netherlands
Bristol-Myers Squibb

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed/Refractory Non-Hodgkin Lymphoma

United States, Spain, France, Netherlands, Switzerland
Mundipharma Research Limited

Active, not recruiting

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Multiple Myeloma | Hodgkin's Lymphoma | Hematological Malignancies | Cutaneous T Cell Lymphoma

France, United States, Netherlands, Spain, Switzerland, Germany, Italy
Bristol-Myers Squibb
Seagen Inc.

Active, not recruiting

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (CheckMate 744)

Hodgkin Disease

United Kingdom, United States, Poland, Spain, Canada, Czechia, France, Germany, Ireland, Italy, Netherlands
MEI Pharma, Inc.
Kyowa Kirin, Inc.

Terminated

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, France, Spain, Korea, Republic of, United Kingdom, Belgium, Japan, Taiwan, Australia, Poland, Italy, Canada, Georgia, Greece, Hungary, Netherlands, New Zealand, Serbia, Turkey
The Netherlands Cancer Institute
Dutch Cancer Society

Completed

To Decrease Fatigue With Light Therapy (SPARKLE)

Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

Netherlands
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Lymphoma

United States, Belgium, Japan, Korea, Republic of, Germany, Hong Kong, Hungary, Netherlands, Singapore
Hoffmann-La Roche

Completed

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma

Hong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
University Medical Center Groningen
Hoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...

Withdrawn

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Netherlands
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

B-Cell Lymphoma

United States, Belgium, Korea, Republic of, Switzerland, France, Poland, Spain, Hong Kong, Australia, Germany, Italy, Netherlands, United Kingdom
Centre for Human Drug Research, Netherlands
Recordati Rare Diseases

Completed

Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides

Mycosis Fungoides

Netherlands
GlaxoSmithKline

Completed

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (Meteor 1)

Neoplasms

United States, Netherlands, Canada, France
University of Giessen
Deutsche Krebshilfe e.V., Bonn (Germany); Euronet Worldwide

Active, not recruiting

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Classical Hodgkin Lymphoma

United Kingdom, Australia, Austria, Belgium, Czechia, Denmark, France, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Slovakia, Spain, Sweden, Switzerland
Hoffmann-La Roche

Completed

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Belgium, Italy, Spain, United States, Canada, Sweden, Greece, Netherlands, Austria, Switzerland, Poland, Turkey, Croatia, Brazil, Argentina, Denmark, United Kingdom
Commissie Voor Klinisch Toegepast Onderzoek
European Organisation for Research and Treatment of Cancer - EORTC

Unknown

Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma

Lymphoma

France, Netherlands, Belgium
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

Lymphoma, Non-Hodgkin | Hodgkin Disease

United States, France, Netherlands, Australia, United Kingdom, Italy, Spain, Germany
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152)

Lymphoma, B-Cell | Non Hodgkin Lymphoma | High-grade B-cell Lymphoma | MYC Translocation | BCL-2 Translocation

Netherlands, Belgium

Clinical Trials on Lymphoma, Hodgkin in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations